This inventor holds 26 USPTO granted patents and 23 published patent applications, plus 2 CIPO patents and 5 EPO patents, primarily in Bi-Specific Fusion Proteins. Top assignees: Merrimack Pharmaceuticals, Inc., Silver Creek Pharmaceuticals, Inc., Torque Therapeutics, Inc.. Active years: 2010-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
19 out of 54 
5 out of 10 
2 out of 4 Years Active: 2010-2026
Areas of Expertise:
Title: Innovations of Ulrik Bjerl Nielsen: A Leader in Bi-Specific Fusion Proteins
Introduction: Ulrik Bjerl Nielsen, based in Quincy, MA, has made significant contributions to the field of biotechnology, particularly through his expertise in bi-specific fusion proteins. With a remarkable portfolio of 24 patents, Nielsen's work not only showcases his innovative spirit but also highlights the potential therapeutic applications of his inventions.
Latest Patents: Among his latest innovations, Nielsen has developed bi-specific fusion proteins that serve various therapeutic purposes. These inventions include pharmaceutical compositions designed to assist in repairing or regenerating damaged or diseased tissue. The bi-specific fusion proteins generally contain two key components: (a) a targeting polypeptide domain that binds to a specific target molecule, and (b) an activator domain that detectably modulates tissue regeneration. Additionally, he has created bi-specific fusion proteins aimed at repairing damaged tissue that feature a targeting polypeptide domain focused on ischemia-associated molecules, along with an activator domain that modulates the activity of cellular networks.
Career Highlights: Throughout his career, Ulrik Bjerl Nielsen has worked with notable companies such as Merrimack Pharmaceuticals, Inc. and Silver Creek Pharmaceuticals, Inc. His dedication to advancing biotechnological solutions has been instrumental in the development of treatments that address critical health issues.
Collaborations: Nielsen has collaborated with esteemed colleagues, including Birgit Schoeberl and Michael Feldhaus. These partnerships have allowed for the cross-pollination of ideas and innovations, strengthening the impact of his contributions in the scientific community.
Conclusion: Ulrik Bjerl Nielsen stands out as a noteworthy inventor in the arena of biotechnology. His work on bi-specific fusion proteins not only exemplifies cutting-edge scientific innovation but also holds the promise of significant therapeutic advancements. As he continues to push the boundaries of biotechnology, it will be exciting to see how his inventions shape the future of medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile